Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

290
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
290
Bioequivalence: Overview01:16

Bioequivalence: Overview

2.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.1K
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

203
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
203
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

360
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
360
Equivalence: In Vitro and In Vivo Bioequivalence01:17

Equivalence: In Vitro and In Vivo Bioequivalence

309
Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts. Pharmaceutical...
309
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs01:20

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

347
Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
347

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Model-Informed Early Prediction of Methotrexate-Induced Acute Kidney Injury in Pediatric Patients with Osteosarcoma Using Real-World Data: A Multi-center Pharmacokinetic Study.

Clinical pharmacokinetics·2026
Same author

Open Systems Pharmacology Community Conference (OSP-CC) Proceedings 2025.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Accelerating tacrolimus model-informed precision dosing in kidney transplant recipients: Model evaluation and refinement strategies.

British journal of clinical pharmacology·2026
Same author

A QSP Model of Valproic Acid Toxicity in Pediatric and Adult Populations: Implications for Formulation Selection and L-Carnitine Supplementation.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Pharmacometrics modeling and simulation to assist phenobarbital dose optimization in dogs.

Frontiers in veterinary science·2025
Same author

Population pharmacokinetics and bioavailability of tacrolimus oral suspension in children with haematopoietic stem cell transplant.

British journal of clinical pharmacology·2025

Related Experiment Video

Updated: Mar 9, 2026

Combining Behavioral Endocrinology and Experimental Economics: Testosterone and Social Decision Making
11:51

Combining Behavioral Endocrinology and Experimental Economics: Testosterone and Social Decision Making

Published on: March 2, 2011

15.8K

Sex Effect on Average Bioequivalence.

Manuel Ibarra1, Marta Vázquez1, Pietro Fagiolino1

  • 1Bioavailability and Bioequivalence Center for Medicine Evaluation, Faculty of Chemistry, Universidad de la República, Montevideo, Uruguay.

Clinical Therapeutics
|December 31, 2016
PubMed
Summary

Generic drug bioequivalence studies often lack sex-based analysis, leading to potentially invalid conclusions. Incorporating sex-specific data is crucial for ensuring generic drug efficacy and safety in all patients.

Keywords:
bioavailabilitybioequivalenceintrasubject variabilitymultisource drug productssex-by-formulation interaction

More Related Videos

Ovariectomy and 17β-estradiol Replacement in Rats and Mice: A Visual Demonstration
06:51

Ovariectomy and 17β-estradiol Replacement in Rats and Mice: A Visual Demonstration

Published on: June 7, 2012

60.0K
Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

1.6K

Related Experiment Videos

Last Updated: Mar 9, 2026

Combining Behavioral Endocrinology and Experimental Economics: Testosterone and Social Decision Making
11:51

Combining Behavioral Endocrinology and Experimental Economics: Testosterone and Social Decision Making

Published on: March 2, 2011

15.8K
Ovariectomy and 17β-estradiol Replacement in Rats and Mice: A Visual Demonstration
06:51

Ovariectomy and 17β-estradiol Replacement in Rats and Mice: A Visual Demonstration

Published on: June 7, 2012

60.0K
Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

1.6K

Area of Science:

  • Pharmacokinetics and Drug Metabolism
  • Clinical Pharmacology
  • Generic Drug Development

Background:

  • Generic drugs are widely prescribed, offering significant cost savings.
  • Ensuring the efficacy and safety of generic formulations is critical.
  • Current bioequivalence studies often underrepresent female subjects and lack sex-based analysis.

Purpose of the Study:

  • To discuss the impact of sex-based physiological differences on bioequivalence conclusions.
  • To highlight the necessity of sex-based analysis in bioequivalence studies for generic drugs.
  • To improve the evaluation and regulatory assessment of generic drug formulations.

Main Methods:

  • Analysis of existing bioequivalence data for oral formulations.
  • Inclusion of studies with at least six male and six female subjects.
  • Estimation of bioequivalence conclusions based on single-sex analysis.

Main Results:

  • Significant sex-by-formulation interactions were observed in 1 of 3 reviewed studies.
  • Over 50% of studies showed significant differences in residual variability between sexes.
  • Bioequivalence conclusions were found to be potentially invalid for one sex in 1 of 3 studies.

Conclusions:

  • Extrapolation of bioequivalence results from males to females is not always scientifically sound.
  • Bioequivalence studies require balanced representation of both sexes for accurate conclusions.
  • Sex-based analysis enhances study design, representativeness, and promotes generic drug safety and efficacy.